1. Outcomes of home parenteral nutrition in 34 patients with intestinal failure from recurrent or progressive peritoneal malignancy of gastro-intestinal tract origin
- Author
-
Sanjeev Dayal, Tom Cecil, Gemma Mason, Allison L. Yates, Alexios Tzivanakis, F. Mohamed, David Richard Swain, Sara Burke, and Brendan J. Moran
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Medicine (miscellaneous) ,030209 endocrinology & metabolism ,Gastroenterology ,Peritoneal malignancy ,03 medical and health sciences ,0302 clinical medicine ,Intestinal failure ,Internal medicine ,medicine ,Retrospective analysis ,Humans ,Pseudomyxoma peritonei ,Peritoneal Neoplasms ,Retrospective Studies ,Bridge to transplant ,030109 nutrition & dietetics ,Nutrition and Dietetics ,business.industry ,medicine.disease ,Appendix ,Intestines ,medicine.anatomical_structure ,Parenteral nutrition ,Digestive tract ,Parenteral Nutrition, Home ,business - Abstract
To investigate the outcomes of 34 patients with intestinal failure secondary to advanced peritoneal malignancy on home parenteral nutrition (HPN). A retrospective analysis of all known patients receiving HPN at any time between January 2012 and the 31st March 2020 registered in a high volume peritoneal malignancy surgical centre database. The median duration of HPN for all patients was 309.5 days (range 31–2198). Overall 11/34 went on to have multivisceral transplants. Of these 5/11 resumed normal oral intake off HPN, 3 died and 3 required ongoing HPN. Average time on HPN for patients with pseudomyxoma peritonei of appendix origin was 338 days (71–2198) compared with 90 days (31–260) in the group with more aggressive tumours. HPN is feasible and effective in selected patients with pseudomyxoma peritonei as either a bridge to transplant or definitive treatment. As expected, patients with more aggressive tumours fare worse.
- Published
- 2020
- Full Text
- View/download PDF